Mar 31
/

Stevanato Group Q1 2025 Earnings Report

Reported revenue of €256.6 million for the first quarter of 2025

Key Takeaways

Stevanato Group reported a 9% increase in revenue for the first quarter of 2025, reaching €256.6 million, primarily driven by strong performance in the Biopharmaceutical and Diagnostic Solutions segment. Gross profit and operating profit margins also improved. The company maintained its full-year revenue guidance but lowered its adjusted EBITDA and adjusted diluted EPS guidance to reflect the estimated impact of recently announced tariffs.

Revenue increased by 9% to €256.6 million in Q1 2025 compared to the prior year.

The Biopharmaceutical and Diagnostic Solutions segment saw 11% revenue growth, offsetting a decline in the Engineering segment.

Gross profit margin improved by 80 basis points to 27.2%, and adjusted operating profit margin increased to 14.3%.

Full-year 2025 guidance for adjusted EBITDA and adjusted diluted EPS was updated to reflect the estimated impact of tariffs.

Total Revenue
€257M
Previous year: €237M
+8.3%
EPS
€0.102
Previous year: €0.0832
+22.2%
Gross Profit Margin
27.2%
Previous year: 26.4%
+3.0%
Adjusted Operating Profit Margin
14.3%
Previous year: 12.3%
+16.3%
Adjusted EBITDA Margin
22.4%
Previous year: 21.4%
+4.7%
Gross Profit
€69.9M
Previous year: €62.4M
+11.9%
Cash and Equivalents
€90.7M
Previous year: €189M
-52.1%
Free Cash Flow
€29.7M

Stevanato Group

Stevanato Group

Stevanato Group Revenue by Segment

Forward Guidance

For fiscal year 2025, Stevanato Group maintains its revenue guidance of €1,160 million to €1,190 million. However, guidance for adjusted EBITDA is updated to €288.5 million to €301.8 million, and adjusted diluted EPS to €0.50 to €0.54, reflecting an estimated €4.5 million tariff impact on operating profit.

Positive Outlook

  • Maintaining full-year revenue guidance (€1,160 million - €1,190 million).
  • Continued strong demand for high-value solutions expected.
  • Expected continued improvements and scaling at Latina and Fishers facilities.
  • Gradual stabilization expected in vial demand as destocking fades.
  • Business fundamentals are strong with favorable secular tailwinds.

Challenges Ahead

  • Lowering adjusted EBITDA guidance (€288.5 million - €301.8 million) due to estimated tariffs.
  • Lowering adjusted diluted EPS guidance (€0.50 - €0.54) due to estimated tariffs.
  • Estimated tariff impact of approximately €4.5 million on operating profit.
  • Ongoing focus on completing legacy projects in the Engineering segment.
  • Anticipating absorption of price increases from suppliers due to tariffs.

Revenue & Expenses

Visualization of income flow from segment revenue to net income